Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | Vitolds Mackēvičs | - |
dc.contributor.author | Nils Uhlemann | - |
dc.contributor.other | Medicīnas fakultāte | lv-LV |
dc.contributor.other | Faculty of Medicine | en-UK |
dc.date.accessioned | 2024-08-14T21:11:32Z | - |
dc.date.available | 2024-08-14T21:11:32Z | - |
dc.date.issued | 2024 | - |
dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/16586 | - |
dc.description | Medicīna | lv-LV |
dc.description | Medicine | en-UK |
dc.description | Veselības aprūpe | lv-LV |
dc.description | Health Care | en-UK |
dc.description.abstract | Aptaukošanās ir satraucoša veselības aprūpes problēma, kas apdraud ne tikai vairāk attīstītās pasaules valstis, bet arī sabiedrību visā pasaulē. Liekais svars ir slimība, kas ir saistīta ar saslimstības un mirstības pieaugumu un pasliktina cilvēku dzīves kvalitāti. Ar aptaukošanos slimo vairāk cilvēku nekā jebkad agrāk, un joprojām nav vērojama tendence, ka aptaukošanās skarto personu skaits samazinās. Gadsimtiem ilgi aptaukošanās skartie cilvēki meklē medicīniskus risinājumus cīņai ar aptaukošanos. Šodien mēs varētu saskarties ar pagrieziena punktu vēsturē. Tirgū ienāk jauni svara samazināšanas medikamenti, kas uzrāda daudzsološu iedarbību, kura ir salīdzināma ar bariatrisko ķirurģiju, tikai ar iknedēļas injekcijām. Tomēr šie medikamenti vēl nav pilnībā izprasti, lai gan tie jau izraisījuši plašas diskusijas sabiedrībā, karstas debates un bieži tiek slavēti kā zāles pret aptaukošanos. Vēsture liecina, ka ir daudz mēģinājumu rast farmakoloģiskus risinājumus šai sarežģītajai metabolisma intervencei, bet ir tikai daži ilgtermiņa veiksmes stāsti. Šī literatūras apskata mērķis ir sniegt ieskatu par pašlaik apstiprinātajiem medikamentiem pret aptaukošanos un salīdzināt to efektivitāti ar riska profilu. | lv-LV |
dc.description.abstract | Obesity represents an alarming health care concern, that does not only threaten more developed countries, but societies all around the globe. Overweight is a condition, that is associated with an increase in morbidity, as well as mortality and decreases quality of life of individuals. More people than ever before are obese and the trend is still not showing a decrease in numbers of affected individuals. For centuries, affected individuals seek medical solutions for their battle against obesity. Today, we could face a turning point in history. New weight-loss drugs are entering the market and show promising effects, that are comparable with bariatric surgery, only by weekly injections. However, those drugs are not yet fully understood, even though they already face a massive public discussion, heated debates and are often praised as cure to obesity. History shows that there are many attempts for pharmacological solutions for this complex metabolic intervention, but only a few long-term success stories. This literature review aims to provide an insight into the currently approved Anti-Obesity medications and compares their effectiveness with their risk profile. | en-UK |
dc.language.iso | en-UK | - |
dc.publisher | Rīgas Stradiņa universitāte | lv-LV |
dc.publisher | Rīga Stradiņš University | en-UK |
dc.rights | info:eu-repo/semantics/closedAccess | - |
dc.subject | Anti-Obesity Medication | en-UK |
dc.subject | AOM | en-UK |
dc.subject | Weight-loss drugs | en-UK |
dc.subject | Obesity | en-UK |
dc.subject | Semaglutide | en-UK |
dc.subject | Tirzepatide | en-UK |
dc.subject | GLP-1 receptor agonists | en-UK |
dc.subject | side effects AOM | en-UK |
dc.title | Comparison of Weight Loss Drug Therapies and their Effectiveness | en-UK |
dc.title.alternative | Svara samazināšanas medikamentozo terapiju un to efektivitātes salīdzinājums | lv-LV |
dc.type | info:eu-repo/semantics/other | en-UK |
Appears in Collections: | Studējošo pētnieciskie darbi |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Medicinas_fakultate_SSNMF_2024_Nils_Uhlemann_037890.pdf | 987.12 kB | Adobe PDF | View/Open Request a copy![]() |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.